A selected protein deficiency that results in liver and lung harm is presently treatable solely with decades-old therapies that each one have limitations. Biotech startup AIRNA is a part of a area of firms growing novel remedies for this inherited dysfunction, and it goals to face aside with a genetic medication it contends may develop into greatest in school. AIRNA is getting ready to advance this program to medical testing and on Wednesday it revealed a contemporary spherical of $60 million to assist its plans.
The illness that Cambridge, Massachusetts-based AIRNA goals to deal with is alpha-1 antitrypsin deficiency, or AATD. This uncommon illness, affecting an estimated 100,000 People, results in low ranges of alpha-1 antitrypsin, a liver protein that suppresses enzymes which might be plentiful when irritation develops. Low alpha-1 antitrypsin ranges lead to progressively worsening harm to the liver, the lungs, or each. This harm can attain the purpose of requiring hospitalization.
Commonplace AATD therapy is intravenous infusions of alpha-1 antitrypsin obtained from wholesome donors. Such augmentation therapies commercially obtainable from CSL Behring and Grifols require weekly dosing. These therapies solely tackle the lung harm from AATD, not liver harm. Different AATD remedies embrace corticosteroids and bronchodilators to open airways and scale back irritation. None of those AATD remedies tackle the underlying reason for the illness. AIRNA goals to take action by enhancing RNA.
“There are not any disease-modifying remedies for AATD biology,” CEO Kris Elverum mentioned. “That biology is especially suited to our expertise. It’s pushed by a mutation in RNA that our expertise can restore.”
The AIRNA remedy is comprised of an oligonucleotide that recruits an enzyme within the physique known as adenosine deaminase appearing on RNA (ADAR). Considered one of ADAR’s roles is to edit RNA, Elverum defined. AIRNA’s platform expertise, known as RESTORE+, permits the corporate to grasp the foundations of enhancing RNA with ADAR. It additionally optimizes the oligonucleotide sequence and chemistry for the remedy. AIRNA’s science comes from the analysis of educational co-founders Thorsten Stafforst, a professor of RNA biochemistry on the College of Tübingen, and Jin Billy Li, a Stanford College professor of genetics.
AIRNA, whose identify comes from the adenosine-to-inosine (A-to-I) RNA enhancing mediated by ADAR, faces competitors from two of its Cambridge neighbors. Each Wave Life Sciences and Korro Bio are growing A-to-I RNA-editing therapies that leverage ADAR. Every biotech additionally claims its remedy is doubtlessly best-in-class. Wave’s preclinical outcomes confirmed its therapeutic candidate, WVE-006, led to AAT protein ranges reaching as much as 30 micromolar, a measure of focus. This remedy is now being evaluated in a randomized, placebo-controlled Part 1/2 research with a focused enrollment of 56 members. The dose-escalation Part 1 portion is underway; Wave expects human proof-of-mechanism information later this 12 months. Beneath an settlement with GSK, the pharma large has world rights to this program and can take over improvement after Wave completes the Part 1/2 research.
Korro Bio’s AATD drug contender, KRRO-110, is on observe for an investigational new drug software within the second half of this 12 months. In mouse research outcomes introduced in January through the J.P. Morgan Healthcare Convention in San Francisco, Korro reported a single dose led to a “best-in-class profile” with secretion of practical AAT protein of about 50 micromolar. In monkey research, Korro reported its remedy activated a transcription issue by making a de novo protein variant whose exercise was sustained for greater than 21 days. Sturdy exams ends in monkeys are considered as an indication {that a} remedy’s impact will translate to people. Further supportive preclinical information had been introduced in Could through the American Thoracic Society 2024 Worldwide Convention.
Just like the experimental Wave and Korro AATD therapies, AIRNA is growing its remedy for subcutaneous administration. Elverum mentioned the corporate will not be but ready to grasp what this remedy’s dosing frequency can be, however he added that he expects physicians and sufferers will desire subcutaneous dosing over the weekly intravenously infused augmentation therapies that make up the present commonplace of care. Requested to specify why he calls AIRNA’s remedy greatest in school, Elverum mentioned particulars from the preclinical analysis haven’t but been publicly launched.
“What we’ve up to now is a best-in-class remedy in comparison with what we’ve seen from others within the area,” he mentioned.
Biopharmaceutical firms are pursuing a variety of approaches for treating AATD. Arrowhead Prescription drugs is growing a small interfering RNA remedy that knocks down manufacturing of mutant variations of the protein to deal with the illness’s results on the liver. This Takeda Pharmaceutical-partnered drug candidate, fazirisiran, is in Part 3 testing. Beam Therapeutics has an in vivo gene-editing remedy in Part 1/2 medical improvement. Vertex Prescription drugs is in early medical improvement with two small molecules designed to appropriate the underlying genetic reason for AATD. Sanofi is a more moderen entrant to this area with an engineered model of the alpha-1 antitrypsin protein presently in mid-stage medical testing. This remedy, developed for month-to-month dosing, comes from Sanofi’s $1.7 billion acquisition of Inhibrx earlier this 12 months.
Elverum mentioned AIRNA’s new capital will assist plans to advance its AATD program to the clinic in 2025. The startup can even broaden its expertise platform and increase its drug pipeline to indications amenable to RNA enhancing, reminiscent of cardiovascular illnesses, metabolic issues, and blood issues. As for locating companions for these applications or for the expertise platform, Elverum mentioned the corporate is open to alliances however will not be actively pursuing them proper now.
AIRNA launched final September with $30 million in Sequence A financing led by Arch Enterprise Companions. The brand new financing introduced Wednesday extends that spherical to $90 million whole. This extra financing was led by Forbion. Different disclosed traders within the new financing are Ono Enterprise Funding and Alexandria Enterprise Investments. Earlier traders Arch and ND Capital additionally participated.
Illustration: Getty Pictures
